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Introduction: The efficacy of pegloticase, a polyethylene glycol (PEG)-conjugated mammalian recombinant uricase,
approved for chronic refractory gout, can be limited by the development of antibodies (Ab). Analyses from 2
replicate, 6-month, randomized controlled trials were performed to characterize Ab responses to pegloticase.
Methods: Anti-pegloticase, anti-PEG, and anti-uricase Ab were determined by validated enzyme-linked
immunosorbent assays. Ab titers were analyzed for possible relationships with serum pegloticase concentrations,
serum uric acid (sUA) lowering, and risk of infusion reactions (IRs).
Results: Sixty-nine (41%) of 169 patients receiving pegloticase developed high titer anti-pegloticase Ab (> 1:2430)
and 40% (67/169) developed anti-PEG Ab; 1 patient receiving placebo developed high titer anti-pegloticase Ab.
Only 14% (24/169) of patients developed anti-uricase Ab, usually at low titer. In responders, patients showing
sustained UA lowering, mean anti-pegloticase titers at week 25 (1:837 ± 1687 with biweekly and 1:2025 ± 4506
with monthly dosing) were markedly lower than in nonresponders (1:34,528 ± 42,228 and 1:89,658 ± 297,797,
respectively). Nonresponder status was associated with reduced serum pegloticase concentrations. Baseline
anti-pegloticase Ab, evident in 15% (31/212) of patients, did not predict subsequent loss of urate-lowering
response. Loss of sUA response preceded IRs in 44 of 56 (79%) pegloticase-treated patients.
Conclusions: Loss of responsiveness to pegloticase is associated with the development of high titer anti-pegloticase
Ab that increase clearance of pegloticase and are associated with a loss of the sUA lowering effect and increased IR risk.
Pre-infusion sUA can be used as a surrogate for the presence of deleterious anti-pegloticase Ab.
Trial registration: NCT00325195. Registered 10 May 2006, NCT01356498. Registered 27 October 2008.Introduction
Hyperuricemia creates the risk for deposition of urate crys-
tals in tissues and increases the risk of developing the
symptoms and signs of gout [1]. One new approach to
urate-lowering is to convert urate to allantoin by adminis-
tering the enzyme uricase, which is mutationally inacti-
vated in humans. Although treatment with recombinant
uricase is an attractive alternative, the enzyme has features
that make it an ineffective pharmaceutical for chronic use,
including poor solubility at physiologic pH, rapid clearance,
and immunogenicity [2,3]. To overcome these obstacles,* Correspondence: peterlipsky@comcast.net
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unless otherwise stated.uricase can be coupled to polyethylene glycol (PEG), creat-
ing a pegylated molecule with reduced immunogenicity,
enhanced solubility, and increased serum half-life [4,5].
Pegloticase is a mammalian recombinant uricase covalently
conjugated to 10 (±1) strands of 10 kDa monomethoxy-
PEG per uricase monomer [6]. Pegloticase has a serum ter-
minal half-life of approximately 214 hours [7], and caused
rapid persistent urate-lowering in response to repetitive ad-
ministration for up to 6 months in approximately 40% of
patients in two replicate, randomized, placebo-controlled
trials (RCTs) [8,9]. Among patients in whom the initial
urate-lowering response to pegloticase was lost subsequent
to the first infusion, high titers of antibodies (Ab) against
pegloticase were demonstrated. The objective of this reporttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Mean serum uric acid (sUA) levels in responders (top
panel) and nonresponders (bottom panel). Values for placebo-
treated patients are shown in the graph of nonresponders.
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with refractory chronic gout. The antigenic specificity of
anti-pegloticase Ab was examined. In addition, the rela-
tionship between anti-pegloticase Ab titers and serum
pegloticase concentrations, serum urate lowering capacity,
and the risk of infusion reactions was also determined.
Methods
Study designs
Over the 6-month RCT [8] treatment period, patients
received biweekly intravenous (IV) infusions consisting
of either pegloticase 8 mg (biweekly cohort), pegloticase
8 mg alternating with placebo (monthly cohort), or pla-
cebo only. The primary endpoint was the number of pa-
tients with a treatment response defined as plasma urate
(pUA) <6.0 mg/dL for ≥80% of the time during months
3 and 6 of the trial. Investigators were blinded to urate
levels during the trials; consequently patients were main-
tained in the trials regardless of responder status, unless
they encountered an adverse event that led to discon-
tinuation from the study, were discontinued for other
reasons, or withdrew consent. A total of 157/212 (74%)
completed the RCTs; all patients withdrawing early were
classified as nonresponders [8]. As previously reported
[8], this study was carried out in accordance with the
Helsinki Declaration, and received institutional review
board approval at each site. Written informed consent
and Health Insurance Portability and Accountability Act
assurances were completed by each participant before
enrollment.
Antibody assays
Sera for measurement of Ab were collected at baseline
and before infusions at weeks 3, 5, 9, 13, 17, 21, and 25
[9]. Ab directed against pegloticase, PEG, and uricase were
measured using validated ELISA (see Additional file 1).
Serum pegloticase levels
Blood samples were collected at baseline, before each infu-
sion, at 1 and 7 days after the week-9 and week-21 infu-
sions, at 7 days after the week-11 and week-23 visits, and
at the final study visit for measurement of serum pegloti-
case concentrations. Samples for determination of trough
pegloticase concentrations were drawn immediately before
the pegloticase infusion and those for peak pegloticase
concentrations were drawn approximately 2 hours follow-
ing infusion completion. An enzymatic/fluorescence assay
was used to quantitate pegloticase concentrations in
serum (see Additional file 1). The lower limit of detection
of serum pegloticase was 0.6 μg/mL.
Statistics
All statistical calculations, including deriving means and
SD, categorical data tests (that is, Chi square or Fisher’sexact test), and correlation analysis based on Pearson
statistics were conducted with SAS 9.3 (Cary, NC, USA).
Results
Responder status and changes in serum uric acid (sUA)
In the modified intent-to-treat (mITT) population, 36 of
85 patients (42.4%) in the biweekly pegloticase cohort and
29 of 84 patients (34.5%) in the monthly pegloticase co-
hort were classified as responders [8]. The remaining 147
patients, including all 43 patients in the placebo cohort,
and all 55 patients who did not complete the study, were
classified as nonresponders. These protocol definitions of
responder and nonresponder were retained in the current
analyses. In all pegloticase-treated patients, sUA declined
rapidly after the first infusion, and mean sUA remained
at <2 mg/dL throughout the treatment period among re-
sponders to biweekly pegloticase (Figure 1). Responders to
monthly pegloticase showed sUA reductions after each
infusion of active treatment, but a saw-tooth pattern was
apparent with increased sUA after the alternating placebo
infusion. Although nonresponders to pegloticase also
achieved a prompt sUA reduction after the first infusion, a
loss in urate-lowering efficacy was seen relatively early
after treatment initiation (Figure 1). Mean time to loss of
uric acid (UA) response among nonresponders in both
dosing cohorts was approximately 6 weeks.
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Among RCT participants treated with pegloticase, 89% had
measurable anti-pegloticase Ab titers during ≥1 study visit.
An empirical approach was employed in an attempt to de-
termine clinically relevant anti-pegloticase Ab titers. This
involved a determination of the titer that most effectively
discriminated between responders and nonresponders.
This approach suggested that a titer >1:2430 might be clin-
ically relevant. Using a titer >1:2430, 69/169 pegloticase-
treated patients (41%) developed high anti-pegloticase Ab
levels (38/85 [45%] in the biweekly group and 31/84 [37%]
in the monthly group).
For UA responders, mean anti-pegloticase Ab titers
were <1:2430 at all study visits (Figure 2), whereas mean
anti-pegloticase Ab titers in nonresponders rose to >1:2430
by the week-4 visit. Importantly, only 2/36 responders in
the biweekly pegloticase cohort and 5/29 responders in the
monthly pegloticase cohort manifested an anti-pegloticase
Ab titer >1:2430 at any time during the trials, compared
with 34/36 and 24/29 responders, respectively, who had
an anti-pegloticase Ab titer ≤1:2430 at all time points
(Additional file 2: Figure S1).
These data strongly suggest that an anti-pegloticase
Ab titer >1:2430 was generally able to distinguish re-
sponders from nonresponders. Notably, when all sam-
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*Mean value at week 17 adjusted for a single incorrect patient value.
Figure 2 Mean anti-pegloticase Ab titers over time among
serum uric acid (sUA) responders and nonresponders (and
placebo-treated patients) receiving biweekly (top panel) and
monthly (bottom panel) pegloticase.between anti-pegloticase Ab titers and sUA was found.
(Additional file 3: Figure S2).
Among placebo-treated patients, 4/43 had anti-
pegloticase Ab at baseline and 8/43 developed anti-
pegloticase Ab during the trials. In general, Ab titers
were very low in patients treated with placebo and no
pattern of increasing titers over time was apparent.
Ig heavy chain isotype of anti-pegloticase Ab
For patients receiving biweekly pegloticase, responders
produced mostly IgM Ab during the first 2 months of
treatment, with the number of patients developing im-
munoglobulin (Ig)G (either with IgM or alone) increas-
ing from week 9 to the end of the study (Figure 3). In
comparison, nonresponders to biweekly pegloticase
already produced both IgM and IgG by week 3, and
most nonresponders produced both IgM and IgG Ab by
the second half of the study. Responders and nonre-
sponders receiving monthly pegloticase showed isotype
patterns similar to those for their counterparts treated
biweekly. Among patients who received placebo and de-
veloped anti-pegloticase Ab, 9/11 produced IgM only.
Patients with positive anti-pegloticase Ab titers at baseline
Fifteen percent (31/212) of patients (including 4 from
the placebo group) had positive anti-pegloticase Ab ti-
ters at baseline. Within the subgroup of 27 patients with
baseline anti-pegloticase Ab treated with pegloticase
during the RCTs, 12 (44%) met the criteria for a UA
responder and 15 (56%) were nonresponders. These pro-
portions are consistent with the UA response rates in
the full study population described above. Mean baseline
anti-pegloticase Ab titers were generally low (1:100 ±
193 in eventual responders and 1:198 ± 546 in eventual
nonresponders) and were predominantly IgM. Among
baseline Ab positive subjects, subsequent Ab titers were
similar to that manifested by the full study cohort. Thus,
for example, at the week-25 assessment, anti-pegloticase
Ab titers were approximately 10-fold higher in nonre-
sponders, albeit with wide variability (1:377 ± 1,143 in
responders and 1:4022 ± 12,517 nonresponders).
Specificity of anti-pegloticase Ab
Pegloticase, the immunogen in this study, is a recombinant
mammalian uricase covalently coupled to 10 ± 1 strands of
10 kDa monomethoxy-PEG per uricase monomer [6].
Therefore, anti-pegloticase Ab could have been directed to
the uricase protein or the PEG moiety or both. To deter-
mine the specificity of the anti-pegloticase Ab, a variety of
PEGylated proteins, including pegloticase, were tested in a
drug competition assay (Table 1). Soluble pegloticase re-
duced binding by 70%. PEG-asparaginase and PEG-catalase
competed with pegloticase to a similar extent, whereas
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Figure 3 Percentage of patients with immunoglobulin (Ig)M and/or IgG anti-pegloticase antibodies (Ab) over time for responders and
nonresponders receiving biweekly and monthly pegloticase.
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level although competition was still apparent. No competi-
tion was noted with the control proteins.
To examine the specificity of the anti-pegloticase Ab re-
sponse in further detail, anti-PEG Ab were measured. A
total of 69/212 patients developed anti-PEG Ab and 64
(93%) of these were UA nonresponders (33 nonresponders
receiving biweekly infusions and 31 nonresponders receivingTable 1 Competition by pegylated and control proteins for b










PEG, polyethylene glycol.monthly infusions). Additionally, three patients who quali-
fied as UA responders and two placebo-treated patients
developed anti-PEG Ab. Mean anti-PEG titers (Additional
file 4: Figure S3) paralleled the pattern and time course of
the mean anti-pegloticase titers.
Ab against the uricase portion of pegloticase (Additional
file 5: Figure S4) were detected in 24 of the 212 patients
(11%) in the mITT population. No placebo-treated patientinding of anti-pegloticase Ab
um High positive control serum
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tient developed anti-uricase Ab before week 13. Of the 24
patients who developed anti-uricase Ab, 13 had only a sin-
gle positive result, and 5 had Ab detected only at the final
visit. Of the total of 40 samples that were positive for anti-
uricase Ab, only 7 were found in samples with a simultan-
eous anti-pegloticase Ab titer of ≤1:2430. Ab that inhibited
uricase activity were extremely rare, with only one possibly
positive result noted in a patient who did not have Ab
detected in the uricase ELISA assay.Anti-pegloticase Ab titers and pegloticase levels
The mean peak serum pegloticase concentration was
1.4 ± 0.1 μg/mL measured 2 hours after the first dose in
responders (n = 36) treated with the biweekly regimen
(Figure 4). This cohort appeared to reach steady state by
the next sampling time at week 9; all subsequent peak
concentration values were in the range of 2.8 to 3.0 μg/mL.
Nonresponders to biweekly infusions (n = 49) had peak
pegloticase levels similar to the responder cohort after their
first dose (1.1 ± 0.1 μg/mL), but concentrations declined
steadily to a mean of 0.2 ± 0.1 μg/mL following the final
dose and only 2/25 patients had detectable values after
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Figure 4 Mean serum pegloticase concentrations in responders
and nonresponders receiving pegloticase biweekly (top panel)
or monthly (bottom panel).0.7 μg/mL for biweekly responders and below 0.05 μg/mL
for biweekly nonresponders at all time points.
This pattern of pegloticase pharmacokinetics was similar
for patients receiving monthly infusions. Mean peak peglo-
ticase levels were similar for responders and nonre-
sponders after the first dose (1.4 ± 0.1 μg/mL versus 1.3 ±
0.1 μg/mL, respectively). Final visit peak concentrations
were 1.7 ± 0.2 μg/mL for monthly responders and 0.2 ±
0.1 μg/mL for monthly nonresponders. Final visit mean
trough values were 0.2 ± 0.1 μg/mL for monthly responders
and undetectable for the monthly nonresponders.
Relationship between the time of UA rise and Ab
response
As previously noted (Additional file 3: Figure S2), there
was a significant correlation (P <0.0001) between sUA
and the anti-pegloticase Ab titer, but the R2 value was
only 0.073, suggesting that additional factors affected
sUA levels. Moreover, it was noted that the titer of anti-
pegloticase Ab at the time the sUA first rose to >6 mg/
dL was variable, with many patients exhibiting low Ab
titers at the time that the urate-lowering efficacy was
lost, regardless of whether pegloticase was administered
biweekly or monthly (Figure 5). However, most patients
who lost their sUA-lowering response eventually devel-
oped high titers of anti-pegloticase Ab (Figure 5). The
pattern of anti-pegloticase Ab titers and loss of sUA over
time is shown in individual patients in Additional file 6:
Figure S5.
Ab titers, UA, and risk of infusion reactions (IRs)
IRs were reported in 22 patients receiving biweekly pegloti-
case, 34 patients receiving monthly pegloticase, and 2 pa-
tients receiving placebo [9]. IRs were more common
among patients who developed high-titer (>1:2430) anti-
pegloticase Ab; 38/56 or 68% of the pegloticase-treated pa-
tients with IRs also had high titer Ab. Similarly, the majority
of patients with IRs had elevated sUA concentrations con-
sistent with loss of efficacy of pegloticase. For example,
among patients treated with the biweekly dose who ex-
perienced IRs (n = 22), 20 patients had sUA >6 mg/dL
before the first IR (one patient had an IR with the first
dose and one patient had an IR with an sUA concentra-
tion <6 mg/dL). Among patients treated with monthly
pegloticase (n = 34), 24 had sUA >6 mg/dL before the
first IR.
Discussion
PEGylation of a recombinant mammalian uricase was
successfully employed to develop a soluble drug, pegloti-
case, with a prolonged serum half-life and robust urate-
lowering efficacy. As uricase is not expressed in humans,
it can be considered a foreign protein, and as such,
would be expected to elicit Ab formation routinely, as is










































Figure 5 Anti-pegloticase antibody (Ab) titer when serum uric
acid (sUA) first exceeded 6 mg/dL and the highest titer
subsequently detected during the randomized controlled trial.
Both sUA and Ab titers were measured in the same samples from
patients defined as nonresponders.
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case, rasburicase [10]. However, the immunogenicity of
pegloticase appeared to be altered by pegylation, in that
even though 89% of subjects generated measurable anti-
pegloticase Ab, only 41% developed high titer Ab with
the capacity to affect drug levels.
PEGylation is known to alter the immunogenicity of
proteins [5]. However, the PEG moiety of the complex
can itself become immunogenic resulting in the for-
mation of Ab reactive against the PEG portion of the
molecule [11]. Multiple lines of evidence support the
conclusion that the PEG moiety is the primary target of
anti-pegloticase Ab. First, competition assays demon-
strated that Ab binding to pegloticase was significantly
reduced by multiple PEGylated proteins. These results
are consistent with other reports on the specificity of
anti-pegloticase Ab [12,13]. Differences in the degree of
competition among the substituted PEGylated proteins
appeared to depend on the molecular weight of the
competitor molecule as well as the extent of PEGylation.
Larger proteins with more PEG strands competed more
effectively than smaller proteins with fewer PEG strands,
suggesting a multiplicity of soluble PEG molecules is re-
quired to compete effectively with Ab binding to pegloti-
case bound to the ELISA plate.Anti-PEG Ab developed contemporaneously with anti-
pegloticase Ab and the titers, albeit lower, paralleled the
anti-pegloticase titers. The lower anti-PEG titers appeared
to relate to differences in the assay such that interference
by pegloticase in the test sera markedly reduced Ab titers.
Despite this, a similar pattern was apparent for anti-
pegloticase and anti-PEG Ab, thus supporting the results
of the competition assays and previously published find-
ings [12]. Moreover, the occurrence and titers of anti-PEG
Ab were associated with a decrease in serum pegloticase
content (unpublished data). These results are all consistent
with the conclusion that most anti-pegloticase Ab are di-
rected to the PEG portion of the molecule.
In contrast to Ab to the PEG portion of pegloticase,
Ab to uricase were infrequent and, when present, usually
developed after considerable exposure to pegloticase and
in subjects with high titers of anti-pegloticase Ab. Previ-
ous data suggest that recombinant uricase does not
competitively inhibit binding of anti-pegloticase Ab to
pegloticase [13], indicating that anti-uricase and anti-
pegloticase Ab represent separate specificities of Ab
binding. Although anti-uricase Ab were more frequent
in nonresponders, the timing of their occurrence, usually
after the UA response was lost, suggests that they were
unlikely to be the cause of the loss of responsiveness,
but rather secondary to prolonged exposure to pegloti-
case in individuals who already had developed high titers
of anti-pegloticase Ab. This conclusion is supported by
the finding that measurable anti-uricase Ab were absent
in many nonresponders. Notably, no evidence was found
to support the possibility that anti-uricase Ab affected
the function of pegloticase.
Two lines of evidence suggest that anti-pegloticase
Ab affected pegloticase pharmacokinetics resulting in
increased clearance and reduced drug concentrations
to sub-therapeutic levels. First, the development of
high-titer anti-pegloticase Ab in nonresponders was as-
sociated with reductions in peak and trough serum
pegloticase concentrations. Second, the anti-pegloticase
Ab had no direct inhibitory effect on pegloticase activity.
Together, these data indicate that the major effect of clin-
ically relevant anti-pegloticase Ab is to alter the pharma-
cokinetics of pegloticase.
Anti-PEG Ab have been reported with administration
of other PEGylated agents. For example, anti-PEG Ab
were closely associated with the rapid clearance of PEG-
asparaginase in a subgroup of patients treated for acute
lymphoblastic leukemia [11]. In contrast, no correlation
was evident between anti-PEG Ab and serum asparagi-
nase activity in control patients who received unmodi-
fied asparaginase. Similarly, anti-PEG Ab have been
associated with enhanced blood clearance of PEG-
modified liposomes and nanoparticles [14-16]. These
findings are all consistent with the current results
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ics of pegloticase.
The relationship between the time of loss of the sUA
lowering effect and the contemporaneous development
of high titer Ab was not immediately apparent while the
clinical trials were ongoing. Indeed, many nonresponders
had low-titer Ab at the time urate-lowering efficacy was
lost, although these patients subsequently developed
higher titer Ab. At the time of the loss of the sUA re-
sponse, it is likely that pegloticase was actually binding
anti-pegloticase Ab, making it impossible to detect the
Ab in the serum samples. Subsequently, as the Ab titers
rose, the capacity of the antigen to bind Ab was super-
seded, and anti-pegloticase Ab could be detected in the
serum. Importantly, the results imply that measuring Ab
levels is not useful for making treatment decisions about
continuing pegloticase treatment.
Nonresponders produced both IgG and IgM Ab,
whereas responders tended to produce more IgM Ab
and for a longer period of time. This suggests that non-
responders have a greater likelihood of developing T-cell
dependent responses with associated increases in Ab ti-
ters and Ig heavy-chain isotype switching [17]. Despite
this, it was not possible to determine whether IgG or
IgM Ab mediated the loss of responsiveness. Although
there was a tendency for the development of IgG Ab to
parallel the loss of responsiveness, a number of subjects
clearly lost responsiveness in the absence of IgG Ab.
Fifteen percent of patients had anti-pegloticase Ab at
baseline, presumably against the PEG portion of the
molecule. In most of these patients the Ab titer was low
and was predominantly IgM. Naturally occurring anti-
PEG Ab, predominantly IgM isotype, were initially re-
ported by passive hemagglutination in 0.2% of healthy
individuals and 3.3% of allergic patients nearly three de-
cades ago [18]. More recent studies have found anti-
PEG Ab in 4% to 25% of healthy blood donors, and have
identified both IgG and IgM isotypes [11,19]. The reason
for anti-PEG Ab in the general population remains to be
determined, but may relate to enhanced assay sensitivity
with ELISA methodology, or more likely, to increased
exposure to PEG-containing products in cosmetics,
processed foods, and pharmaceuticals [2,11,20,21]. In
the present study, there was no evidence that the pres-
ence of anti-pegloticase Ab at baseline was related to
risk of nonresponse to pegloticase.
To determine whether specific patient characteristics
were associated with an increased likelihood of develop-
ing anti-pegloticase Ab, a number of demographic char-
acteristics including age, gender, body mass index, and
renal function were examined. The only one of these
that was significantly associated with responsiveness was
age. For example, 50% of subjects who were 60 years of
age or older were responders to pegloticase compared to30% of those under 60 (P = 0.015). Indeed, 61% of subjects
who were 70 or older were responders. These data suggest
that age may be a determinant of Ab formation and
responsiveness. Whether this association relates to general
age-related immunoinsufficiency, with a lesser capacity to
generate T-cell help [22], or a greater likelihood to become
tolerized to PEG with increasing age is unknown.
Conclusions
Clinically significant anti-pegloticase Ab, present in 41% of
patients, increased pegloticase clearance and did not
neutralize uricase activity. Anti-pegloticase Ab were largely
directed to the PEG portion of the molecule. Responders
to pegloticase typically had low-titer Ab, whereas nonre-
sponders usually developed high-titer Ab. Importantly, Ab
titers at the time of study-visit infusions were not predict-
ive of loss of sUA response, whereas loss of sUA response
was predictive of IR risk. Patients with clinically significant
anti-pegloticase Ab can be identified by loss of the sUA re-
sponse, prompting treatment discontinuation.
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determinations at each study visit in all evaluable responders and
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(PEG) antibody (Ab) titers over time for the pegloticase dosing groups by
uric acid (UA) responder status.
Additional file 5: Figure S4. Individual anti-uricase antibody (Ab) titer
determinations for patients with positive anti-uricase Ab at any study visit
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dose and response type.
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